Optimized Molecular Entities







Optimized molecular entities are target-relevant small molecules whose drug-like properties have been optimized for preclinical screening. These OMEs have been derived from cores from our BDC collections. We apply our in-depth knowledge to design and synthesize these molecules. We believe that OMEs have a greater likelihood of success to become development candidates. Currently, we have a 100-membered library that is available for immediate pilot screening. CreaGen continues to produce new libraries and make them available for partners screening.

Capabilities 

• Rapid design and synthesis of OME libraries for Lead Discovery and Optimization
• Cycle times of 3-4 weeks from design to delivery
• All compounds purified by reverse phase HPLC
• All compounds quantified and characterized by LCMS (UV214, UV254) and NMR spectroscopy

Capacity 

• 10,000 OME library compounds annually
• Typical quantities of 5-10 mg
• Supplied in DMSO solution (96-well plates) or in powder form

Please contact our R & D Coordinator for more information.


Fax, email or phone inquiries.


CreaGen Inc.,

299 Washington Street,
Woburn, MA 01801

Dr. Raj Rajur, Ph.D., Chairman & CEO

Voice +1 (781) 938-1122 ext. 112
Fax +1 (781) 938-1123
rrajur@creageninc.com

Ms . Anny Chum, Project manager & Director of operations & Administration

Voice (781) 938-1122 ext. 111
Fax (781) 938-1123
anny@creageninc.com



Subscribe


Sign up for CreaGen Inc newsletter to receive all the news.




Social networks



Twitter

#WeCare




Contact us




Send us an email

rrajur@creageninc.com



Subscribe


Sign up for Medicare newsletter to receive all the news offers and discounts from Medicare eye clinic.




Social networks



Twitter

#WeCare





© CreaGen Inc 2019. All rights reserved. Designed by Inqude



© CreaGen Inc 2019. All rights reserved. Designed by Inqude